Originally published July 30.

Myriad Genetics will use its BRACAnalysis test to pick out best responders to PM1183, a new type of DNA-damaging agent that drug developer Pharma Mar is studying as a potential treatment for advanced breast cancer.

Under this latest companion diagnostics agreement involving its flagship BRACAnalysis test, Myriad will assess the BRCA status of metastatic breast cancer patients enrolled in a Phase II study investigating Pharma Mar's PM1183.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.